Hairstetics, an Israeli innovator in the non-absorbable polyamide hair transplant sector, has achieved a milestone with the implementation of its system at Hainan Boao LuYi Hospital, marking the first use case in Asia. The company’s cutting-edge technology addresses the complex and often slow-progressing condition of female androgenetic alopecia, a disease characterized by a multifaceted etiology and an intricate treatment process.
Androgenetic alopecia affects a significant patient population in China, with current treatment options focusing on disease management through delaying or preventing progression and promoting partial hair follicle regeneration. Despite the availability of various treatment methods, the treatment timeline is extended, necessitating patience and commitment from both patients and medical practitioners.
The next-generation product by Hairstetics offers a minimally invasive surgical implantation on the scalp, designed for simplicity, ease of operation, and brevity. The implant is reversible and can be removed as needed, facilitating multiple hair transplant procedures.
Hainan Boao LuYi Hospital, known for its adoption of advanced medical solutions, has previously implemented 20 specialized drug-devices and has successfully passed acceptance checks across 12 medical disciplines, reinforcing its reputation for medical innovation.- Fineline.com
